Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer
- 16 February 2011
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 67 (7) , 693-700
Abstract
Paclitaxel has a broad spectrum of anti-tumor activity and is useful in the treatment of ovarian, breast, and lung cancer. Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by P-glycoprotein. The dose-limiting toxicities are neuropathy and neutropenia, but the interindividual variability in toxicity and also survival is large. The main purpose of this study was to investigate the impact of genetic variants in CYP2C8 and ABCB1 on toxicity and survival.Keywords
This publication has 30 references indexed in Scilit:
- Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancerThe Pharmacogenomics Journal, 2010
- Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicityThe Pharmacogenomics Journal, 2010
- Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian CancerBasic & Clinical Pharmacology & Toxicology, 2009
- ABCB1(MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin ChemotherapyClinical Cancer Research, 2008
- ABCB1 G1199A Polymorphism and Ovarian Cancer Response to PaclitaxelJournal of Pharmaceutical Sciences, 2008
- No Evidence for Taxane/Platinum Pharmacogenetic Markers: Just Lack of Power?Journal of Clinical Oncology, 2008
- Ethnic Considerations in Pharmacogenetic StudiesJournal of Clinical Oncology, 2008
- Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian CancerJournal of Clinical Oncology, 2007
- Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropeniaEuropean Journal of Cancer, 2006
- mdr-1Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel ChemotherapyClinical Cancer Research, 2006